Biosimilar Etanercept

    Project Code: 168
    Etanercept is a fusion protein (150 kDa) that is produced by recombinant DNA. It is used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF) by acting as a TNF inhibitor. It also has the potential to treat a variety of other disorders mediated by excess TNF.
Project Overview
The etanercept molecule is made up of 934 amino acids, with a weight of 150 Kda. It is made from the combination of two naturally occurring soluble human 75-kDa TNF receptors linked to an Fc portion of an IgG1. The effect is an artificially engineered dimeric fusion protein Manufacturing is based on expression via protein recombinant technology, in Chinese Hamster Ovary (CHO) cell-lines. Its mode of action is as a TNFα blocker. TNFα is a kind of cytokine that is produced by monocytes and macrophages. It increases the flow of white blood cells to the site of inflammation. It can thus be said that through this function, coupled with several other related mechanisms, TNFα could potentially increase inflammation. In response, etanercept decreases inflammation responses through inhibiting the afore-mentioned TNFα mechanism; this is an effective means in treatment of autoimmune diseases.

You may also like